Osimertinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approved
Selectivity scorecard
KISS
97.24
Gini
0.733
CATDS
0.019
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Osimertinib. Strongest target: ERBB4_HER4 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 100.0% | 0.0% |
| 2 | ERBB2_HER2 | 99.4% | 0.6% |
| 3 | EGFR | 99.1% | 0.9% |
| 4 | TXK | 97.6% | 2.4% |
| 5 | JAK3 | 97.5% | 2.5% |
| 6 | ROS_ROS1 | 97.2% | 2.8% |
| 7 | BTK | 96.3% | 3.7% |
| 8 | TNK1 | 92.8% | 7.2% |
| 9 | ACK1 | 92.6% | 7.4% |
| 10 | MYO3B | 90.9% | 9.1% |
| 11 | BLK | 90.0% | 9.9% |
| 12 | MNK1 | 86.2% | 13.8% |
| 13 | BRK | 85.8% | 14.2% |
| 14 | ITK | 85.4% | 14.6% |
| 15 | LRRK2 | 82.4% | 17.6% |
| 16 | TNIK | 81.3% | 18.7% |
| 17 | ALK | 80.5% | 19.5% |
| 18 | YSK4_MAP3K19 | 79.7% | 20.3% |
| 19 | BMX_ETK | 79.5% | 20.5% |
| 20 | TEC | 74.6% | 25.4% |
Selectivity landscape
Where Osimertinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Osimertinib.
Annotations
Sign in to read and post annotations.
Loading…